[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
-
Add time:07/15/2019 Source:sciencedirect.com
Introduction[11C]Erlotinib PET has shown promise to distinguish non-small cell lung cancer (NSCLC) tumors harboring the activating epidermal growth factor receptor (EGFR) mutation delE746-A750 from tumors with wild-type EGFR. To assess the suitability of [11C]erlotinib PET to detect the emergence of acquired erlotinib resistance in initially erlotinib-responsive tumors, we performed in vitro binding and PET experiments in mice bearing tumor xenografts using a range of different cancer cells, which were erlotinib-sensitive or exhibited clinically relevant resistance mechanisms to erlotinib.
We also recommend Trading Suppliers and Manufacturers of Erlotinib hydrochloride (cas 183319-69-9). Pls Click Website Link as below: cas 183319-69-9 suppliers
Prev:Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay
Next:The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host–guest detection by β-Cyclodextrin nanoparticles modified glassy carbon electrode) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing Erlotinib hydrochloride (cas 183319-69-9)07/19/2019
- Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer07/18/2019
- Simultaneous determination of temperature and erlotinib by novel carbon-based sensitive nanoparticles07/17/2019
- The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host–guest detection by β-Cyclodextrin nanoparticles modified glassy carbon electrode07/16/2019
- Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay07/14/2019
- Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application07/13/2019
- Recrystallization of Erlotinib hydrochloride (cas 183319-69-9) and fulvestrant using supercritical antisolvent process07/12/2019
- Use of roller compaction and fines recycling process in the preparation of Erlotinib hydrochloride (cas 183319-69-9) tablets07/11/2019
-
Health and Chemical more >